August 17, 2020 10:59 AM EDTUpdated 01:05 PM
R&D
FDA+

Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

Nicole DeFeudis

Editor

It was an­i­mal da­ta on G1 Ther­a­peu­tics’ on­col­o­gy drug tri­laci­clib that orig­i­nal­ly at­tract­ed cur­rent CEO Mark Vel­le­ca to the com­pa­ny six years ago. And now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

A service from the Financial Times